Older adults who do not take medicine older adults
Conditions
Interventions
Participants will be randomized in 2 groups:
NMN 1,250 mg (5 tablets of 250 mg) orally, once a day, 24 weeks
Placebo (5 tablets) orally, once a day, 24 weeks
Nicotin Amide Mononucleotide (NMN)
Sponsors
Yamauchi Toshimasa
MIRAILAB BIOSCIENCE Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Non-smoker 2. Aged 65 years old or older at the time of informed consent is taken 3. Male or female 4. Able to attend all scheduled visits 5. Able and willing to give written informed consent
Exclusion criteria
Exclusion criteria: 1. Taking health food 2. With severe hearing loss or wearing a hearing aid in daily life 3. Taking more than 1 hour daily exercise for more than 6 months 4. With a pacemaker 5. Taking medicine, including Chinese medicine 6. Having history of treatment for cancer, heart failure and myocardial infarction 7. With atrial fibrillation, arrhythmia, liver failure, renal failure, cerebrovascular disease, rheumatoid arthritis and other chronic diseases except diabetes, dyslipidemia and hypertension 8. Suspected of having viral hepatitis, HIV or syphilis 9. With drug allergy or with food allergy to health food related to this study 10. Participated in other clinical trials within 3 months 11. Judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in hearing ability after 24 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Change from baseline in the following items related to aging after 24 weeks of treatment. 1.Physical function 2. Blood tests 3. Biomarkers 4. DNA methylation age 5. Skin condition 6. Exercise tolerance assessed by the 6 minute walk test 7. Gut and oral microbiota 8. Number of mitochondria 9. Quality of Life 2) Correlation between blood NAD level and these items. | — |
Contacts
Public ContactYuriko Takaoka
The University of Tokyo Hospital
Outcome results
None listed